← Human Trials & Peer-Reviewed Studies
Effects of Cholecalciferol Supplementation in Patients with stable heart failure and LOw vITamin D levels (ECSPLOIT-D): a double-blind, randomized, placebo-controlled pilot study.
Plain-language guide to PMID 28565886 (2017): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc in 35 patients.
Key Facts
- PMID
- 28565886
- Journal
- Minerva cardioangiologica
- Year
- 2017
- Study type
- Randomized Controlled Trial
- Authors
- Turrini F et al. (10 authors)
- DOI
- 10.23736/S0026-4725.17.04340-7
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.
The aim of this study was to investigate the effects of vitamin D (VD) on the interaction among functional, echocardiographic and hormonal parameters in patients with heart failure (HF) and VD deficiency.
Who Took Part
According to the abstract, 35 patients were involved.
PubMed indexes the participants as older adults and people over 80, both men and women.
How the Study Was Run
The design is described as randomized, double-blind, placebo-controlled and pilot.
Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.
Neither the patients nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.
Some patients received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.
It is described as a pilot, a small early test of whether a larger Vitamin D, K2, Magnesium and Zinc study would be practical.
What Was Measured
Topics PubMed links to this paper include Cholecalciferol, Dietary Supplements, Echocardiography, Exercise Test, Heart Failure, Pilot Projects and Vitamin D Deficiency.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 35 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2017 (Minerva cardioangiologica), a journal based in Italy.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.